Pancreatic Cancer Research

ResearcherHeidelberg UniversityActive in the last 2 years

Alexander Muckenhuber

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0414-1797; OpenAlex author ID A5067504399. Sources: OpenAlex.

Their work

Papers
23 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
122
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 5 papers · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: 3 papers · 2025: 3 papers · 2026: 1 paper

Papers 23

  1. Contrastive virtual staining enhances deep learning-based PDAC subtyping from H&E-stained tissue cores. First author DOI 10.1002/path.6491↗
  2. Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA. Co-author DOI 10.1002/1878-0261.13747↗
  3. Pancreatic cancer cells survive in the neural niche during neoadjuvant therapy. Co-author DOI 10.1016/j.canlet.2025.217894↗
  4. Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. Co-author DOI 10.1016/j.ccell.2025.09.003↗
  5. KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry-based subtyping. Last author DOI 10.1002/2056-4538.12377↗
  6. Lymph node examination and survival in resected pancreatic ductal adenocarcinoma: retrospective study. Co-author DOI 10.1093/bjsopen/zrad125↗
  7. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2024.1378190↗
  8. Phenotype screens of murine pancreatic cancer identify a Tgf-α-Ccl2-paxillin axis driving human-like neural invasion. Co-author DOI 10.1172/jci166333↗
  9. Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. Co-author DOI 10.1053/j.gastro.2021.03.051↗
  10. PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. Co-author DOI 10.1172/jci.insight.141532↗
  11. [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13550-021-00808-4↗
  12. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Co-author DOI 10.1136/gutjnl-2018-317856↗
  13. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells. Co-author DOI 10.1158/1078-0432.ccr-19-1864↗
  14. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. Co-author DOI 10.1172/jci.insight.137809↗
  15. Image-Based Molecular Phenotyping of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm9030724↗
  16. Multiparametric Modelling of Survival in Pancreatic Ductal Adenocarcinoma Using Clinical, Histomorphological, Genetic and Image-Derived Parameters. Co-author DOI 10.3390/jcm9051250↗
  17. A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX … Co-author DOI 10.1371/journal.pone.0218642↗
  18. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-17-2180↗
  19. pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2017.06.034↗
  20. High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrosp… Co-author DOI 10.1016/j.pan.2017.04.012↗
  21. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.4038↗
  22. Ataxia-telangiectasia-mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicat… Co-author DOI 10.1097/mpa.0000000000000248↗
  23. High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/1471-2407-13-450↗

Closest collaborators

The 25 strongest of 122 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. İhsan Ekin Demir · 10 shared papers, 2017–2025 · strength 1.46
  2. Guralp Onur Ceyhan · 9 shared papers, 2017–2025 · strength 1.10
  3. Wilko Weichert · 14 shared papers, 2013–2021 · strength 1.05
  4. Helmut Friess · 7 shared papers, 2017–2025 · strength 0.95
  5. Helmut Frieß · 8 shared papers, 2019–2025 · strength 0.92
  6. Roland Michael Schmid · 9 shared papers, 2019–2025 · strength 0.91
  7. Rickmer Braren · 8 shared papers, 2019–2026 · strength 0.86
  8. Carmen Mota Reyes · 5 shared papers, 2020–2025 · strength 0.81
  9. Jens Thomas Siveke · 6 shared papers, 2019–2026 · strength 0.77
  10. Hana Algül · 6 shared papers, 2019–2025 · strength 0.62
  11. Kaan Çifcibaşı · 3 shared papers, 2023–2025 · strength 0.52
  12. Maximilian Reichert · 5 shared papers, 2020–2023 · strength 0.47
  13. Okan Safak · 3 shared papers, 2020–2025 · strength 0.46
  14. Georgios A. Kaissis · 5 shared papers, 2019–2021 · strength 0.44
  15. Roland Rad · 4 shared papers, 2020–2025 · strength 0.43
  16. Dieter Saur · 4 shared papers, 2020–2025 · strength 0.43
  17. Rüdiger Göß · 2 shared papers, 2024–2025 · strength 0.42
  18. Ilaria Pergolini · 2 shared papers, 2024–2025 · strength 0.42
  19. Sebastian Ziegelmayer · 4 shared papers, 2019–2021 · strength 0.38
  20. Fabian Karl Lohöfer · 4 shared papers, 2019–2021 · strength 0.38
  21. Kıvanç Görgülü · 3 shared papers, 2021–2025 · strength 0.37
  22. Anna Melissa Schlitter · 4 shared papers, 2017–2021 · strength 0.31
  23. Maximilian Kießler · 2 shared papers, 2023–2024 · strength 0.30
  24. Felix N. Harder · 3 shared papers, 2020–2021 · strength 0.29
  25. Friederike Jungmann · 3 shared papers, 2020–2021 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.